A Phase Ib/II Randomized Study of BI 836845 in Combination With Exemestane and Everolimus Versus Exemestane and Everolimus Alone in Women With Locally Advanced or Metastatic Breast Cancer
收藏DataCite Commons2025-10-16 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/PR00011863/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
Phase Ib / II study to determine the Maximum Tolerated Dose and Recommended Phase II Dose, and to evaluate the safety and antitumour activity, of BI 836845 and everolimus in combination with exemestane in women with HR+/HER2- advanced breast cancer
提供机构：
Vivli
创建时间：
2025-10-15
